Inflarx Stock Price, News & Analysis

InflaRx N.V. (Nasdaq: IFRX) announced the initiation of a Phase III trial for vilobelimab targeting hidradenitis suppurativa (HS) patients with active draining tunnels. The study will use a new primary endpoint, the modified HiSCR, to assess the reduction of inflammatory nodules, abscesses, and draining tunnels. Patient enrollment is set to commence in Q2 2022, following FDA support for the trial design. A virtual R&D event scheduled for February 3, 2022, will provide further insights into the study. Over 300 individuals have previously received vilobelimab in clinical trials.

InflaRx (Nasdaq: IFRX) announced encouraging results from its Phase II IXCHANGE study of vilobelimab in ANCA-associated vasculitis (AAV). The study showed that vilobelimab matched the efficacy of standard glucocorticoids while significantly reducing their usage and associated toxicity. In total, 57 patients participated in the trial, demonstrating high clinical response rates across treatment groups. Notably, vilobelimab alone had the least treatment-emergent adverse events. The company plans to consult regulatory authorities to discuss the next steps for vilobelimab's development.

InflaRx (Nasdaq: IFRX) will present a corporate overview at the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, at 8:00 am EST/2:00 pm CET. The presentation will be accessible through a live webcast on the company's website. InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, with a special emphasis on its proprietary anti-C5a technology. Founded in 2007, the company operates in Germany and the USA.

InflaRx reported positive developments for vilobelimab, focusing on treatment for Hidradenitis Suppurativa (HS) and Pyoderma Gangraenosum (PG). The FDA endorsed a new primary endpoint for HS, while in PG, 6 of 7 patients achieved clinical remission in a Phase IIa study. The company secured a €43.7 million grant from the German government to advance vilobelimab for severe COVID-19. As of September 30, 2021, InflaRx had approximately €120.6 million in cash and equivalents, despite a net loss of €33 million for the nine months ended. Topline COVID-19 data is expected in Q1 2022.

InflaRx (Nasdaq: IFRX) announced that Prof. Niels C. Riedemann, CEO and Founder, will present a corporate overview during a fireside chat at the Credit Suisse 30th Annual Healthcare Conference. The session is scheduled for November 10, at 9:40 am EST/3:40 pm CET, and will be accessible via a live webcast on the InflaRx website. InflaRx focuses on developing anti-inflammatory therapeutics by targeting the complement system, specifically inhibitors of C5a, which is crucial in autoimmune and inflammatory diseases.

InflaRx N.V. (Nasdaq: IFRX) announced promising results from its Phase IIa study of vilobelimab for Pyoderma Gangraenosum (PG). In the highest dose cohort, 85.7% of patients demonstrated clinical remission, with no dose-related adverse events reported. The study enrolled 19 patients, showing significant efficacy at various dosages. InflaRx plans to seek FDA guidance for a pivotal program based on these results. A conference call will be held today at 8:30 am EDT to discuss this data further.

InflaRx N.V. (Nasdaq: IFRX) has been awarded a grant of up to EUR 43.7 million by the German government to support the development of vilobelimab for COVID-19 treatment. The initial tranche of EUR 25.8 million will reimburse 80% of specified expenses related to clinical development and manufacturing. The grant aims to expedite vilobelimab's development and secure manufacturing capacity in Germany. The ongoing Phase III study is fully enrolled, with top-line results expected in Q1 2022.

InflaRx N.V. (Nasdaq: IFRX) has completed enrollment in the Phase III portion of its vilobelimab study, which targets severe COVID-19 patients. The study enrolled 369 patients in multiple countries, including Europe and South America. Topline results are anticipated in Q1 2022, focusing on 28-day all-cause mortality among other endpoints. The Phase II part showed a mortality rate of 13% in the vilobelimab arm versus 27% in the control group. Vilobelimab is a promising anti-C5a antibody aimed at treating various inflammatory conditions.

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, announces that CEO Prof. Niels C. Riedemann will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand from 7:00 AM EDT / 1:00 PM CET on September 13, 2021. A webcast of the event can be accessed for 90 days on the InflaRx website in the Investors section.

InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, specifically through its proprietary anti-C5a technology.